75.37 USD
-1.5 (-1.95%)
Overall TARS gets a fundamental rating of 4 out of 10. We evaluated TARS against 190 industry peers in the Pharmaceuticals industry. TARS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TARS shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year TARS has reported negative net income.
TARS had a negative operating cash flow in the past year.
In the past 5 years TARS always reported negative net income.
In the past 5 years TARS reported 4 times negative operating cash flow.
1.2 Ratios
TARS has a better Return On Assets (-15.18%) than 62.11% of its industry peers.
TARS has a better Return On Equity (-24.22%) than 64.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| ROIC | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TARS has a Gross Margin of 93.26%. This is amongst the best in the industry. TARS outperforms 94.74% of its industry peers.
TARS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TARS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TARS has more shares outstanding
TARS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TARS has a worse debt to assets ratio.
2.2 Solvency
TARS has an Altman-Z score of 9.73. This indicates that TARS is financially healthy and has little risk of bankruptcy at the moment.
TARS's Altman-Z score of 9.73 is amongst the best of the industry. TARS outperforms 82.11% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that TARS is not too dependend on debt financing.
TARS's Debt to Equity ratio of 0.22 is in line compared to the rest of the industry. TARS outperforms 43.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.73 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
TARS has a Current Ratio of 4.29. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
TARS has a Current ratio of 4.29. This is in the better half of the industry: TARS outperforms 61.05% of its industry peers.
TARS has a Quick Ratio of 4.25. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
TARS has a better Quick ratio (4.25) than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.29 | ||
| Quick Ratio | 4.25 |
3. Growth
3.1 Past
TARS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.98%, which is quite impressive.
The Revenue has grown by 182.44% in the past year. This is a very strong growth!
Measured over the past years, TARS shows a very strong growth in Revenue. The Revenue has been growing by 47.48% on average per year.
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
Revenue 1Y (TTM)182.44%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
3.2 Future
Based on estimates for the next years, TARS will show a very strong growth in Earnings Per Share. The EPS will grow by 36.25% on average per year.
TARS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.55% yearly.
EPS Next Y51.69%
EPS Next 2Y60.48%
EPS Next 3Y52.04%
EPS Next 5Y36.25%
Revenue Next Year153.71%
Revenue Next 2Y97.09%
Revenue Next 3Y71.47%
Revenue Next 5Y46.55%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
TARS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 42.27, TARS can be considered very expensive at the moment.
69.47% of the companies in the same industry are more expensive than TARS, based on the Price/Forward Earnings ratio.
TARS is valuated expensively when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 42.27 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TARS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TARS's earnings are expected to grow with 52.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.48%
EPS Next 3Y52.04%
5. Dividend
5.1 Amount
TARS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TARS (1/12/2026, 1:58:32 PM)
75.37
-1.5 (-1.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.04%
Inst Owner Change-0.25%
Ins Owners3.09%
Ins Owner Change-1.29%
Market Cap3.20B
Revenue(TTM)366.10M
Net Income(TTM)-81.16M
Analysts86.25
Price Target88.63 (17.59%)
Short Float %17.15%
Short Ratio13.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.85%
Min EPS beat(2)-17.77%
Max EPS beat(2)16.07%
EPS beat(4)3
Avg EPS beat(4)8.3%
Min EPS beat(4)-17.77%
Max EPS beat(4)20.78%
EPS beat(8)7
Avg EPS beat(8)12.73%
EPS beat(12)10
Avg EPS beat(12)11.89%
EPS beat(16)13
Avg EPS beat(16)13.53%
Revenue beat(2)2
Avg Revenue beat(2)3.09%
Min Revenue beat(2)0.99%
Max Revenue beat(2)5.19%
Revenue beat(4)4
Avg Revenue beat(4)5.95%
Min Revenue beat(4)0.99%
Max Revenue beat(4)11.62%
Revenue beat(8)8
Avg Revenue beat(8)30.02%
Revenue beat(12)9
Avg Revenue beat(12)39.62%
Revenue beat(16)10
Avg Revenue beat(16)13.76%
PT rev (1m)1.92%
PT rev (3m)17.87%
EPS NQ rev (1m)13.18%
EPS NQ rev (3m)-9.95%
EPS NY rev (1m)2.37%
EPS NY rev (3m)-2.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 42.27 | ||
| P/S | 8.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.55 | ||
| P/tB | 9.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.02
EYN/A
EPS(NY)1.78
Fwd EY2.37%
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS8.62
BVpS7.89
TBVpS7.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.26% | ||
| FCFM | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 474.96% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.29 | ||
| Quick Ratio | 4.25 | ||
| Altman-Z | 9.73 |
F-Score5
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)439.33%
Cap/Depr(5y)393.66%
Cap/Sales(3y)12.37%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
EPS Next Y51.69%
EPS Next 2Y60.48%
EPS Next 3Y52.04%
EPS Next 5Y36.25%
Revenue 1Y (TTM)182.44%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
Revenue Next Year153.71%
Revenue Next 2Y97.09%
Revenue Next 3Y71.47%
Revenue Next 5Y46.55%
EBIT growth 1Y37.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.71%
EBIT Next 3Y59.8%
EBIT Next 5Y49.54%
FCF growth 1Y33.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.39%
OCF growth 3YN/A
OCF growth 5YN/A
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you provide the ChartMill fundamental rating for TARSUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to TARS.
What is the valuation status for TARS stock?
ChartMill assigns a valuation rating of 2 / 10 to TARSUS PHARMACEUTICALS INC (TARS). This can be considered as Overvalued.
Can you provide the profitability details for TARSUS PHARMACEUTICALS INC?
TARSUS PHARMACEUTICALS INC (TARS) has a profitability rating of 2 / 10.